Agenus Inc.
Anti-PD-1 antibodies and methods of use thereof
Last updated:
Abstract:
The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Status:
Grant
Type:
Utility
Filling date:
24 Apr 2020
Issue date:
31 May 2022